A Phase 1, Open Label, Dose Escalation, Single Oral Dose Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066.
Phase of Trial: Phase I
Latest Information Update: 28 Nov 2011
At a glance
- Drugs Crizotinib (Primary)
- Indications Neuroblastoma; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- 20 Jan 2011 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 22 Dec 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 07 Dec 2010 New trial record